Alzheimer' s Disease (AD) is a progressive neurodegenerative disease, which is pathologically defined by the accumulation of amyloid plaques and hyper-phosphorylated tau aggregates in the brain. Mitochondrial dysfunction is also a prominent feature in AD, and the extracellular Aβ and phosphorylated tau result in the impaired mitochondrial dynamics. In this study, we generated an induced pluripotent stem cell (iPSC) line from an AD patient with amyloid precursor protein (APP) mutation (Val715Met; APP-V715M) for the first time. We demonstrated that both extracellular and intracellular levels of Aβ were dramatically increased in the APP-V715M iPSC-derived neurons. Furthermore, the APP-V715M iPSC-derived neurons exhibited high expression levels of phosphorylated tau (AT8), which was also detected in the soma and neurites by immunocytochemistry. We next investigated mitochondrial dynamics in the iPSC-derived neurons using Mito-tracker, which showed a significant decrease of anterograde and retrograde velocity in the APP-V715M iPSC-derived neurons. We also found that as the Aβ and tau pathology accumulates, fusion-related protein Mfn1 was decreased, whereas fission-related protein DRP1 was increased in the APP-V715M iPSC-derived neurons, compared with the control group. Taken together, we established the first iPSC line derived from an AD patient carrying APP-V715M mutation and showed that this iPSC-derived neurons exhibited typical AD pathological features, including a distinct mitochondrial dysfunction.
INTRODUCTION
Alzheimer' s Disease (AD) is a progressive neurodegenerative disease, and AD patients exhibit loss of memory that impairs their ability to learn or carry out daily tasks. Pathologically, AD can be characterized by the accumulation of amyloid plaques and hyper-phosphorylated tau aggregates which causes neuronal loss in the brain [1, 2] . AD can be divided into sporadic and autosomal-dominant familial forms. The latter form is rare, but very tragic, given its 100% penetrance to the family members who have the causative mutations. The autosomal-dominant form of AD is associated with mutations in amyloid precursor protein (APP), presenilin-1 (PS1), or presenilin-2 (PS2) [3] . It has been demonstrated that the APP C-terminal mutations including APP (V715M) exhibited increased Aβ 42 secretion in primary neurons [4, 5] . The APP (Val715Met; APP-V715M) mutation was detected in Korea and the patient showed typical clinical symptoms [6] . In this study, we generated an induced pluripotent stem cell (iPSC) line from an AD patient with APP-V715M mutation for the first time. We characterized the phenotypes of APP-V715M iPSC-derived neurons, including extracellular and intracellular levels of Aβ and high expression levels of phosphorylated tau, compared with the elderly normal control iPSC line which has been fully characterized in our previous study [7] . We investigated the mitochondrial dynamics and the expression of fission and fusion-related proteins in the iPSC-derived neurons. APP-V715M iPSC-derived neurons exhibited decrease of mitochondrial velocity and impaired balance of mitochondrial fission and fusion, indicative of extracellular Aβ or phosphorylated tau-induced impairment of mitochondrial dynamics [8] [9] [10] [11] . Taken together, we established an iPSC line, for the first time, from a middle-aged AD patient with an APP-V715M mutation, which recapitulats the cardinal features of AD pathophysiology, which will be potentially useful to develop biomarkers associated with disease progression and responses to the diseasemodifying therapies.
MATERIALS AND METHODS

Enrollment of participants
The patient met the criteria for AD as recommended by the National Institute on Aging-Alzheimer's Association, and the normal elderly subject fulfilled the criteria of a normal elderly control as defined by Christensen, et al [12, 13] . We performed detailed neuropsychological tests, MRI, [ 18 F]-Florbetaben amyloid PET, and blood draw for iPSC generation from each participant. The institutional review board of the Samsung Medical Center, Asan Medical Center, and CHA University approved the study protocol, and informed written consent was obtained from each participant.
Characterization and differentiation of iPSCs
Mononuclear cells (MNCs) were isolated freshly from the peripheral blood of the APP-V715M patient using the FicollPaque TM PLUS method (GE Healthcare, USA) [7] . Isolated peripheral-derived MNCs (PBMCs) were infected with SeVdp (KOSM) 302L [14] . Genotyping of the APP-V715M single nucleotide mutation was performed by DNA sequencing (Cosmo Genetech, Korea). The APP gene was amplified by PCR using the following primers (forward primer: TTC AAG GTG TTC TTT GCA GA; reverse primer: CAT AGT CTT AAT TCC CAC TTG G). For teratoma formation, undifferentiated iPSCs were harvested and subcutaneously transplanted into NOG mice. Teratomas were dissected and fixed with 4% paraformaldehyde (PFA) at 8 to 16 weeks after injection. Paraffin-embedded tissue was sectioned and stained with hematoxylin/eosin to detect the formation of threegerm layer tissue morphology. Karyotyping, Sendai virus detection PCR, in vitro and cortical differentiation were performed as we described before [7, 14] .
Extracellular and intracellular amyloid-β ELISA
Extracellular Aβ levels were measured using conditioned media (CM), which were collected from cultured neuronal cells (1×10   5   ) at 48 hours after the last medium change from 8 and 10 weeks of differentiation. Intracellular Aβ 42 and Aβ 40 were measured in a total of 1µg proteins from 10 week-differentiated neurons. All procedures were essentially same as described before [7] .
Immunocytochemistry and Western blot
Immunocytochemistry and Western blot analysis were performed as described before [7] . The following primary antibodies were used: anti-OCT4 ( 
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imaging (LCI) analysis. Cells were maintained at 37℃ and were supplied with atmosphere of 5% CO 2 /95% air (Live Cell Instrument, Seoul, Korea) during imaging. Time-lapse image recording were acquired in 2 sec interval and duration up to 4 min 30 sec. Mitochondria kymographs were analyzed using KymographClear, an ImageJ macro toolset that allows for the generation of kymographs from image sequences. Quantitative analysis of mitochondria velocity was performed using KymographDirect, a standalone tool to extract quantitative information from kymographs in an automated way with high accuracy and reliability [15] .
Statistical analysis
All statistical analyses were performed using the Student' s t test or one-way analysis of variance (ANOVA) following the Fisher' s LSD (Least Significant Difference) in the Statistical Analysis System (Enterprise 4.1, SAS Korea, Seoul, Korea). Significance was accepted at the 95% probability level. Data in graphs were presented as mean ± SEM. Statistical significance (i.e., p value) in the graphs were presented as follows: p<0.05 (*), p<0.01 (**) and p<0.001 (***).
RESULTS AND DISCUSSION
Clinical features of the patient
This study is based on a 54 year-old man with an APP mutation (Exon17; c.2143G>A; p.V715M) who visited the memory disorder clinic of Asan Medical Center (Seoul, Korea). The patient developed symptoms at the age of 49, starting with memory impairment and attention deficits. He subsequently developed an impairment in daily activities at the age of 52. Neurological examination revealed a generalized cognitive impairment with the mini-mental state examination (MMSE) score of 10. Treatments with cholinesterase inhibitor and NMDA receptor antagonist had limited effects. By the age of 54, the patient developed bradykinesia and rigidity, and no longer understood verbal commands. MRI taken at the age of 54 showed a generalized cortical atrophy, and the 18 F-Florbetaben amyloid PET showed a significant amyloid accumulation in the bilateral striatum and association cortices (Fig.  1A) . The patient had a strong family history of dementia with an autosomal dominant pattern (Fig. 1B) . A 72 year-old healthy man with normal cognition was enrolled for the study. He showed no brain atrophy on brain MRI and no significant amyloid accumulation on amyloid PET (Fig. 1A) . Informed written consent was obtained from each participant.
To investigate the pathological features of the patient with APP-V715M mutation, we generated an iPSC line from an AD patient carrying the APP-V715M mutation using the technology that we developed for iPSC generation [7] . The APP patient-derived MNCs were reprogrammed using Sendai virus vector (SeVdp) which expresses four reprogramming factors (OCT3/4, SOX2, cMYC, and KLF4) [7, 14] . For iPSC generation, we picked more than three individual clones and selected the best growing clone for further analyses. iPSC lines harboring the APP-V715M mutation exhibited the typical expression of pluripotent stem cell markers, including OCT4, SOX2, SSEA4 and TRA-1-81 ( Fig. 2A) . Differentiation potential of iPSC lines was assessed using in vitro embryoid body formation and in vivo teratoma assays, based on the three-germ layer marker expression (Fig. 2B and 2F ). Genotyping of the established iPSC line was confirmed by a conventional sequencing method (Fig. 2C) . No SeVdp vector was integrated in the established iPSC line (Fig. 2D ) and its karyotype was normal (Fig. 2E) . Although the effects of overexpression of the APP-V715M mutation on Aβ secretion have been studied in primary neurons previously [4, 5] , little has been known about the pathological features of the patients carrying the APP-V715M mutation at cellular levels. To investigate the Aβ levels in the APP-V715M iPSCderived neurons, we measured Aβ 40 and Aβ 42 levels both extracellularly and intracellularly at 10 weeks of neuronal differentiation.
No significant difference in Aβ 40 level was detected. However, the APP-V715M iPSC-derived neurons exhibited a dramatic increase in Aβ 42 level (i.e., over 2-fold) at 10 weeks of differentiation. Importantly, the ratio of Aβ 42 /Aβ 40 was significantly increased (i.e., over 2-fold) in the APP-V715M iPSC-derived group, compared with the control group (Fig. 3A) . To detect the Aβ deposits, the iPSC-derived neurons were stained with anti-Aβ 42 antibody at 10 weeks of neural differentiation. Notably, confocal microscopy images showed a robust increase in the extracellular Aβ 42 deposits in the APP-V715M iPSC-derived neurons, compared to the control (Fig. 3B) . Furthermore, we extracted the TBS-insoluble/ SDS-soluble fraction according to the previous protocols [16, 17] . The TBS-insoluble/SDS-soluble intracellular Aβ 42 and Aβ 40 levels were measured in a total 1µg of proteins using ELISA at 10 weeks of neuronal differentiation. Levels of the intracellular Aβ 42 and the ratio of Aβ 42 /Aβ 40 were significantly increased in the APP-V715M iPSC-derived neurons (Fig. 3C) . Western blot analysis showed that the expression level of total APP was significantly decreased in the APP-V715M iPSC-derived neurons ( Fig. 3D and 3E ). By contrast, the Aβ oligomers showed a significant increase in the APP-V715M AD-iPSC (APP-V715M) iPSC-derived neurons, compared with the control (Fig. 3D and  3F) . It has been recently demonstrated in vitro that the increase and accumulation of Aβ peptides can lead to the formation of neurofibrillary tangles consisting of aggregated hyperphosphorylated tau [16] . Tau protein normally exists as a soluble form in the axons of mature neurons. However, when it becomes hyperphosphorylated, p-tau protein abnormally accumulates in the dendrites and the cell bodies in AD [18, 19] . To investigate the p-tau levels in the APP-V715M iPSC-derived neurons, we performed an immunocytochemical analysis using an antibody against AT8 (phosphorylated at Ser202/Thr205). We found that the APP-V715M iPSCderived neurons exhibited a significant increase of AT8 expression in the neurites and the soma, compared with the control group (Fig.  3G~I) . Furthermore, we performed Western blot to measure the AT8 protein levels and found that the APP-V715M iPSC-derived neurons showed an increase of tau levels, compared with the control group (Fig. 3J~L) . Taken together, we demonstrated that the APP-V715M iPSC-derived neurons exhibited significant increases both in extracellular and intracellular Aβ levels and increased levels of p-tau levels, compared with the control group. To investigate the mitochondrial dynamics, we performed the live cell imaging analysis using Mito-tracker (Ds-Red) at 10 weeks of neuronal differentiation. We found that the APP-V715M iPSCderived neurons showed a reduced movement compared with the control group (Supplementary movie files 1 and 2). Kymograph (Fig. 4A ) and the quantification analysis of mitochondria velocity were performed using KymographClear and KymographDirect, respectively [15] . Both anterograde and retrograde velocity were significantly decreased in the APP-V715M iPSC-derived neurons compared with the control group ( Fig. 4B and 4C) . Furthermore, we investigated the expression levels of mitochondrial fusion and fission-related proteins at 6 and 10 weeks of neuronal differentiation, including mitochondria fusion-related protein Mfn1 (membrane proteins mitofusin 1), Mfn2 (membrane proteins mitofusin 2) and mitochondria fission-related proteins DRP1 (dynaminrelated protein 1) and Fis1 (mitochondrial fission 1 protein). There was no significant difference of fusion and fission-related protein expression in the control and APP-V715M iPSC-derived neurons at 6 weeks of neuronal differentiation. At 10 weeks of neuronal differentiation, Western blot analysis revealed that Mfn1 expression was dramatically reduced, whereas DRP1 expression levels were significantly increased in the APP-V715M iPSC-derived neurons, compared with the control neurons ( Fig. 4D and 4E) . In accordance with previous reports, in which accumulated Aβ and p-tau affect mitochondrial functions, our results strongly suggest that high levels of Aβ and p-tau may disrupt the mitochondrial transport, presumably due to the impaired balance of mitochondrial fusion and fission in the APP-V715M iPSC-derived neurons.
Mitochondria plays an important role in neuronal function and survival, and mitochondrial dysfunction is one of the most prominent features in the AD brains [9] . We investigated the mitochondrial dynamics in the APP-V715M iPSC-derived neurons, which exhibited a dramatic decrease of mitochondria movement as well as the anterograde and retrograde mitochondrial velocity using Mito-tracker (Supplementary movie files 1, 2 and Fig. 4) . Mitochondrial dynamics is determined by the constantly repeating process of fusion and fission, and this process is tightly regulated by the balance of fusion and fission-related proteins [10, 20] . As extracellular Aβ and phosphorylated tau are implicated in the impairment of mitochondrial fission and fusion processes in humans [10, 20, 21 ], we measured the expression level of fusion and fissionrelated markers at 6 and 10 weeks of neuronal differentiation, because APP-V715M iPSC-derived neurons showed a significant increase in Aβ levels from 8 weeks of neuronal differentiation (Fig.   Fig. 3 AD-iPSC (APP-V715M) 3A). Western blot analysis revealed that the expression of fissionassociated markers was significantly increased, but fusion-related markers were significantly decreased in the APP-V715M iPSC-derived neurons at 10 weeks. However, this difference was not clearly detected at 6 weeks of neuronal differentiation (Fig. 3D and 3E ). Based on these findings, we speculated that the increased Aβ secretion and phosphorylated tau proteins can lead to the defective mitochondrial axonal transport and the imbalance of mitochondrial fission and fusion in the APP-V715M iPSC-derived neurons.
In summary, we generated an iPSC line from AD patient with the APP-V715M mutation for the first time. We also characterized the pathological features of APP-V715M iPSC-derived neurons, including increased levels of extracellular and intracellular Aβ as well as phosphorylated tau, and identified that mitochondrial dysfunction may be a key contributing factor to AD pathophysiology in the APP-V715M iPSC-derived neurons.
